- Home
- MGX vs NTRB Comparison
MGX vs NTRB Comparison
Compare MGX & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGX
- NTRB
- Stock Information
- Founded
- MGX 2018
- NTRB 2016
- Country
- MGX United States
- NTRB United States
- Employees
- MGX N/A
- NTRB N/A
- Industry
- MGX
- NTRB Industrial Specialties
- Sector
- MGX
- NTRB Health Care
- Exchange
- MGX NYSE
- NTRB Nasdaq
- Market Cap
- MGX 62.1M
- NTRB 59.1M
- IPO Year
- MGX 2024
- NTRB N/A
- Fundamental
- Price
- MGX $1.45
- NTRB $7.50
- Analyst Decision
- MGX Strong Buy
- NTRB Buy
- Analyst Count
- MGX 4
- NTRB 1
- Target Price
- MGX $13.00
- NTRB $13.00
- AVG Volume (30 Days)
- MGX 417.1K
- NTRB 82.0K
- Earning Date
- MGX 08-13-2025
- NTRB 05-30-2025
- Dividend Yield
- MGX N/A
- NTRB N/A
- EPS Growth
- MGX N/A
- NTRB N/A
- EPS
- MGX N/A
- NTRB N/A
- Revenue
- MGX $45,263,000.00
- NTRB $2,398,437.00
- Revenue This Year
- MGX N/A
- NTRB $560.75
- Revenue Next Year
- MGX $11.75
- NTRB $588.39
- P/E Ratio
- MGX N/A
- NTRB N/A
- Revenue Growth
- MGX N/A
- NTRB 18.92
- 52 Week Low
- MGX $1.23
- NTRB $3.72
- 52 Week High
- MGX $5.50
- NTRB $11.78
- Technical
- Relative Strength Index (RSI)
- MGX 40.18
- NTRB 59.79
- Support Level
- MGX $1.41
- NTRB $7.00
- Resistance Level
- MGX $1.59
- NTRB $7.90
- Average True Range (ATR)
- MGX 0.13
- NTRB 0.66
- MACD
- MGX -0.02
- NTRB -0.01
- Stochastic Oscillator
- MGX 11.32
- NTRB 37.45
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.